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Abstract
Background: Sepsis remains a major cause of mortality in critical care, for which specific treatments are lacking.
The dysregulated response to infection seen in sepsis includes features of lymphocyte dysfunction and exhaustion,
suggesting that immune-stimulatory therapy may improve outcomes in certain patient groups. Monoclonal
antibodies targeting checkpoint molecules, such as programmed-death 1 protein (PD-1) and its ligand PD-L1, have
shown success in stimulating the immune response in patients with cancer, and are being considered for future
sepsis trials. The aims of this pilot study were to compare lymphocyte subset expression of PD-1 and its ligands
between patients with sepsis and controls; to characterize serum levels of PD-1 and PD-L1 in patients with sepsis
and controls, and determine if serum concentrations correlated with cell surface expression.
Methods: Expression levels of PD-1, PD-L1 and PD-L2 on four lymphocyte subsets (CD27 + CD19+ B cells, CD27-CD19+
B cells, CD27 + CD4+ T cells and CD27-CD4+ T cells) were compared between 22 patients with sepsis (including 11
survivors and 11 non-survivors) and 11 healthy controls using flow cytometry. Levels of soluble PD-1 and PD-L1 were
also compared using commercially available ELISA kits.
Results: Expression of PD-1 and PD-L1 was higher on all lymphocyte subsets in patients with sepsis compared to
controls (p < 0.05). PD-L2 expression on CD27+ B cells was also higher in patients with sepsis (p = 0.0317). There was
differential expression of PD-1 by CD27 status, with expression being higher in the B and T cell subsets associated with
memory status (CD27+ and CD27-, respectively; p < 0.001). Higher PD-1 and PD-L1 expression was not associated with
mortality or with a higher risk of nosocomial infection. There were no differences in levels of soluble PD-1 or PD-L1
between patients with sepsis and controls.
Conclusions: Higher expression of PD-1 by memory subpopulations of B cells and CD4+ T cells, with normal soluble
PD-1 and PD-L1 in patients with sepsis, are novel findings. This information may be useful to enrich sepsis populations
for trials of PD-1/PD-L1 blockade.
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Background
Sepsis is a dysregulated host response to infection [1],
with concomitant immune activation and suppression.
Sepsis-related immunosuppression contributes to poor
outcomes by increasing the risk of nosocomial infection
and death [2–4]. A common feature of sepsis-related im-
munosuppression is impaired lymphocyte function, with
increased expression of inhibitory checkpoint molecules,
such as programmed-death 1 protein (PD-1) [2]. PD-1
serves to limit excessive immune responses by negatively
regulating lymphocyte activation and function, and
promoting immune cell apoptosis. It has two known
ligands: programmed death ligand-1 (PD-L1), which is
widely expressed by a variety of immune and non-
immune cell types; and programmed death ligand-2
(PD-L2), which is expressed by antigen-presenting cells
[2]. Increased expression of PD-1 and PD-L1 by T cells,
monocytes and neutrophils has been demonstrated in
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sepsis, while upregulation of the PD-1 pathway is associ-
ated with higher mortality [2, 5–8]. As this dysfunction is
potentially reversible with anti-PD-1 or anti-PD-L1 mono-
clonal antibody treatment [2, 5–8], manipulating the PD-1
pathway represents a potential target for sepsis trials.
Against this background, we hypothesized that lympho-
cyte surface PD-1, PD-L1 and PD-L2 expression by B and
T cell subsets will vary by CD27 expression status. CD27
is a marker of lymphocyte activation; CD27 positive
(CD27+) B cells correspond to memory B cells [9], while
CD27 negative (CD27-) T cells represent a high antigen-
recall subset of memory T cells [10]. Another rationale for
assessing CD27-based memory lymphocyte subsets is the
selective depletion of memory B cells in sepsis [8]; it is not
known whether PD-1 expression varies by lymphocyte
memory status. We therefore measured PD-1, PD-L1 and
PD-L2 surface expression on CD27+ and CD27- subsets
of CD4+ T and B lymphocytes using flow cytometry in
adult patients with sepsis on the intensive care unit (ICU).
We compared expression between patients with sepsis
and healthy controls, and between subgroups of patients
with sepsis by nosocomial infection and survival status.
PD-1 and PD-L1 also exist in a soluble form in serum;
however, the relevance of these soluble forms to sepsis
pathogenesis is unclear. We hypothesized that cell-surface
PD-1, PD-L1 and PD-L2 expression would correlate with
serum concentrations, and so we measured corresponding
serum PD-1 and PD-L1 levels in the same samples.
Methods
Conceptual approach
Immune responses in sepsis differ between patients [3, 4].
The ability to identify who would – or would not – benefit
from therapy based on specific biological mechanisms will
offer a crucial step forward in patient management, espe-
cially when that mechanism is dominant, linked to an out-
come of interest, and present at the time of assessment of
trial eligibility [11]. These principles informed our study
design. Our conceptual approach was that sepsis trial
eligibility criteria are often assessed on the day of ICU
admission and that patients with increased expression of
PD-1 and PD-L1 have a greater risk of nosocomial infec-
tions and/or death, as this would be a dominant mechan-
ism contributing to these outcomes.
Study design and setting
This was an analysis of a subpopulation of patients en-
rolled into a previous prospective observational cohort
study performed in a general medical-surgical tertiary
ICU (HRA Research Ethics Committee approval refer-
ence: 12/LO/0326). Details of the study design have been
published previously [8, 12]. From this cohort we ran-
domly selected 22 adult patients with sepsis, with an
ICU length of stay ≥48 h, and included equal numbers
of survivors and non-survivors [8, 12]. As our original
study was designed prior to the Sepsis-3 definitions, sep-
sis was identified using the previous definition requiring
proven or suspected infection, two or more systemic in-
flammatory response system (SIRS) criteria, and at least
one organ system dysfunction (cardiovascular, respira-
tory, renal, haematologic, hepatic, neurologic or meta-
bolic) [13]. We highlighted in a recent cohort study that
the prevalence of SIRS-negative sepsis in ICU patients in
England was approximately 3% [14], with a 92% overlap
in sepsis cases identified by Sepsis-2 and Sepsis-3 [15].
We excluded patients less than 18 years old, and those
with known immune dysfunction, including those with
congenital hypogammaglobulinaemia, known protein-
losing enteropathies, nephrotic syndrome and neoplastic
or proliferative haematologic diseases; those having re-
ceived intravenous immunoglobulin therapy in the last
3 months; those receiving high-dose corticosteroid ther-
apy; those with ongoing blood loss (defined by blood
transfusion requirement > 2 units in a 24 h period); those
with retroviral disease; and those with immune dysfunc-
tion as defined by Acute Physiology and Chronic Health
Evaluation (APACHE) II score comorbidities [16].
Blood sampling, flow cytometry, ELISA and healthy
controls
Peripheral blood mononuclear cells were isolated by
density centrifugation from blood samples collected
within 12 h of ICU admission and stored in liquid nitro-
gen. Serum samples from the same patients were stored
at − 80 °C. Anti-human fluorochromes were used to
identify lymphocyte subsets: anti-CD19 (PerCP Cy5.5;
HB19); anti-CD3 (APC-H7; SK7) (both BD Biosciences,
Wokingham, Berkshire, UK); anti-CD4 (Pacific Blue;
SK3); anti-CD27 (FITC; 0323); anti-PD-1 (APC; EH12.
2H7); anti-PD-L1 (PeCy7; 29E.2A3); and anti-PD-L2
(PE; 24F.101C12) (all Biolegend, London, UK). Amcyan
(L34957; Invitrogen, Carlsbad, CA, USA) was used to
identify live cells. All flow cytometry experiments were
carried out by the same investigator. Flow cytometer set
up, calibration and compensation were carried out prior
to each experiment using BD CompBeads (BD
Biosciences). Reagents remained the same during the
course of the study. Gating to identify cell subsets was
achieved using isotype controls and fluorescence minus-
one (FMO) controls (Additional file 1: Figure S1). FlowJo
software (https://www.flowjo.com) was used for analysis
of flow cytometry data. Percentage positivity for PD-1,
PD-L1 and PD-L2 was defined as the percentage of cells
above the gate set using the above controls, with the
proportion of positive cells and the corresponding geo-
metric mean fluorescence intensity (MFI) used as indica-
tors of expression. Serum levels of PD-1 and PD-L1
were quantified in duplicate using commercial ELISA
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kits (Proteintech, Manchester, UK), according to the man-
ufacturer’s instructions. Detection ranges for PD-1 and
PD-L1 were 125–8000 pg/ml and 0.156–10 ng/ml, re-
spectively. All flow cytometry and ELISA experi-
ments were based on anonymised healthy controls
who gave consent prior to sampling as per the
King’s College London Infectious Diseases Biobank
protocol [8].
Statistics
Mann-Whitney U tests were used to compare PD-1,
PD-L1 and PD-L2 expression on B and T cells be-
tween septic patients and controls, and between sub-
groups of septic patients based on mortality and
nosocomial infection status, with nosocomial infection
defined as a new antibiotic start for suspected new
infection, after an antibiotic-free period ≥24 h. Within
patients with sepsis, PD-1, PD-L1 and PD-L2 ex-
pression on B and T cells was compared by CD27
status using the paired Wilcoxon test. All statistical
analyses were performed with GraphPad Prism soft-
ware (GraphPad Software, La Jolla, CA, USA). Signifi-
cance levels were set as p values < 0.05.
Results
Study cohort
The median (IQR) age of the septic patients was 68.5
(54.8 – 84.3) years, with 73% male. The respiratory tract
was the most common infection site (73%), followed by
intra-abdominal (18%) and wound/soft tissue (9%). The
mean (SD) total white cell and lymphocyte counts were
15.9 (7.8) × 109 cells/l and 1.1 (0.7) × 109 cells/l,
respectively. The median (IQR) ICU length of stay was
10.5 (7–20) days. Nosocomial infection occurred in 11
patients and was more common in patients with an ICU
length of stay ≥ 4 days (61% vs 0%). Patient characteristics
are summarized in Additional file 2: Table S1 and
Additional file 3: Table S2.
Memory B cells in patients with sepsis had more PD-1,
PD-L1 and PD-L2 positive cells with higher expression
The proportion of B cells positive for PD-1 and the cor-
responding MFI were significantly greater in patients
with sepsis than in controls (26.5% vs 8.8%, p = 0.0002;
483 vs 348, p = 0.0003) (Additional file 4: Table S3;
Fig. 1): this was true of both CD27+ and CD27- subsets
(Additional file 5: Table S4; Additional file 6: Figure S2;
Fig. 1 Programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) expression on B cells. a-c Comparison of the mean fluorescence
intensity (MFI) of PD-1, PD-L1 and PD-L2 on B cells in patients with sepsis compared with healthy controls. d-f Comparison of the MFI of PD-1,
PD-L1 and PD-L2 between CD27+ B cells and CD27- B cells within patients with sepsis. The boxes below show the corresponding proportion of
positive cells for each comparison, with corresponding p values. *Significant p values
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Additional file 7: Figure S3). The proportion of PD-L1
positive B cells was also greater in patients with sepsis
compared to healthy controls (2.4% vs 1.2%, p = 0.0244).
The percentage positivity of PD-L2 was higher in sepsis
than controls in the CD27+ subset only (3.59% vs 0.41%,
p = 0.0317) (Additional file 7: Figure S3). Within B cells in
septic patients, the CD27+ subset had significantly higher
PD-1 and PD-L2 MFI (574.5 vs 471.5, p < 0.0001; 1189 vs
744, p < 0.0001) and percentage positivity (34.05% vs
24.80%, p < 0.0007; 3.59% vs 0.86%, p < 0.0001) (Fig. 1).
Memory CD4+ T cells in patients with sepsis had more
PD-1, PD-L1 and PD-L2 positive cells with higher
expression
The proportions of PD-1 and PD-L1 positive T cells were
significantly greater in sepsis than in controls (38.90% vs
21.25%, p = 0.0023; 1.9% vs 0.2%, p = 0.0083), as were the
corresponding MFI values (780 vs 627, p = 0.0013; 1314 vs
1007, p = 0.0276) (Fig. 2): this was true of CD27+ and
CD27- subsets (p < 0.05 for all comparisons) (Additional
file 5: Table S4; Additional file 8: Table S5; Additional file 9:
Figure S4; Additional file 10: Figure S5). There were no sig-
nificant differences in CD4+ T cell PD-L2 expression be-
tween patients with sepsis and healthy controls. In patients
with sepsis, expression of PD-1 was higher on CD27- T
cells than CD27+ T cells, by both percentage positivity and
MFI (70.45% vs 35.15%, p < 0.0001; 972 vs 716, p < 0.0001)
(Fig. 2).
Admission-day PD-1, PD-L1 and PD-L2 expression did not
differ by nosocomial infection and hospital mortality
There were no differences in PD-1, PD-L1 or PD-L2
expression between patients who subsequently devel-
oped a nosocomial infection and those who did not
(Additional file 11: Figure S6). When patients with an ICU
length of stay ≤ 7 days were excluded, PD-L1 expression on
lymphocytes was significantly higher in those who subse-
quently developed an infection (p= 0.0068) (Additional file 12:
Figure S7); however, this was not statistically significant for
any B or T cell subset (Additional file 13: Figure S8). There
were no differences between survivors and non-survivors in
PD-1, PD-L1 or PD-L2 expression for any lymphocyte
subset (Additional file 14: Figure S9).
Soluble PD-1 and PD-L1 expression did not correlate with
cell surface expression
There were no differences in serum soluble PD-1 (sPD-1)
and sPD-L1 concentrations between patients with sepsis
Fig. 2 Programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) expression on CD4+ T cells. a-c Comparison of the mean
fluorescence intensity (MFI) of PD-1, PD-L1 and PD-L2 on T cells in patients with sepsis compared with healthy controls. d-f Comparison of the
MFI of PD-1, PD-L1 and PD-L2 between CD27+ T cells and CD27- T cells within patients with sepsis. The boxes below show the corresponding
proportion of positive cells for each comparison, with corresponding p values. *Significant p values
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and healthy controls (Additional file 15: Figure S10).
There was no correlation between serum sPD-1 and
sPD-L1 concentrations in patients with sepsis and lympho-
cyte surface expression (Additional file 16: Figure S11).
Discussion
The novel findings from this pilot study include the first
report of higher B cell expression of PD-1, PD-L1 and
PD-L2 in sepsis, and differential expression of PD-1 by
CD27 status in both B and CD4+ T cells. We also report
results that are consistent with the published literature
such as higher PD-1 and PD-L1 expression in CD4+ T
cells in sepsis compared with controls [7, 17], which
gives external validity to our report. The overexpression
of these checkpoint inhibitors in most patients with sep-
sis is consistent with the published literature suggesting
this is a feature of sepsis-related immunosuppression.
PD-L2 has been less well-studied in sepsis than PD-L1,
as PD-L1 is the more important binding partner for PD-1.
The contribution of PD-L2 to the pathophysiology of sep-
sis remains unknown although increased PD-L2 expres-
sion by monocytes was reported in one observational
study of patients with septic shock [7]. A key finding of
our present study in critically ill adult patients with sepsis
was higher expression of PD-1/PD-L in the lymphocyte
subsets associated with memory status, i.e. CD27+ B cells
and CD27- CD4+ T cells. Memory lymphocytes are
formed after encountering a specific pathogen, and are
vital for generating rapid and effective immune responses
upon future encounters with the same pathogen [18]. We
chose CD27 as a marker of memory status. CD27 expres-
sion is associated with activation in circulating B cells [9].
CD27+ B cells are larger and exhibit greater and more
rapid proliferation and immunoglobulin production in re-
sponse to antigenic stimulation [9]. In CD4+ T cells, loss
of CD27 expression is seen in memory cells at a late stage
in differentiation, and is associated with an increased cap-
acity for IL-4 production [19]. Functional studies of CD4+
T cells report that CD27 expression distinguishes two dis-
tinct subpopulations, of which the CD27- subset shows a
stronger antigen-recall response and increased cytokine
secretion [10]. Relatively higher PD-1 expression on
CD27- T cells may therefore have a greater negative effect
on antigen-specific responses in both B cells and T cells,
as there is T cell-dependent B cell development within the
germinal centers of secondary lymphoid organs [20].
We measured soluble PD-1 (sPD-1) and sPD-L1 levels,
as high levels of sPD-1 or sPD-L1 in sepsis could reduce
the efficacy of anti-PD-1 or anti-PD-L1 antibody therapy
by neutralisation. Furthermore, should serum levels cor-
relate with cell surface expression this may offer a po-
tential point-of-care biomarker to identify patients who
could benefit from early PD-1 pathway blockade. We did
not find any significant differences in sPD-1 or sPD-L1
levels between patients with sepsis and controls; of note,
levels were towards the lower limit of detection in the
majority of subjects. Previous studies measuring serum
sPD-1/L levels in sepsis have yielded inconsistent results
[21–23] (Additional file 17: Table S6). Importantly, con-
current cell surface expression was not measured in any
of these studies. Timing of measurement may contribute
to the differences; we measured sPD-1/PD-L1 within
12 h of ICU admission whereas the others varied from
time of presentation to the emergency department [21]
to within 24 h of ICU admission [22, 23]. Our pilot
study results suggest that sPD-1 or sPD-L1 levels within
12 h of ICU admission do not identify patients with high
cell surface PD-1/L expression [11]. This needs confirm-
ation in larger cohorts, ideally using the same inclusion
criteria as those planned for interventional trials.
In contrast to one previous study [7], we did not ob-
serve significant differences in PD-1/PD-L1 expression
by either survival or nosocomial infection status. Aside
from our small sample size, there are several alternative
explanations. The kinetics of these checkpoint inhibitors
is unknown in critically ill patients with sepsis. There is
also a variable degree of immunosuppression even at the
time of ICU admission though we specifically excluded
any patients with previously documented immunosup-
pression. However, our timing of sampling within 12 h
of ICU admission may be too early for differentiating
survival status. This inference is supported by a recent
study examining PD-1 expression by CD4+ T cells in a
sepsis cohort using serial measurements on days 1, 3
and 7 of ICU admission, which found that while all sep-
tic patients had raised PD-1 at days 1 and 3, only survi-
vors had normalised PD-1 expression by day 7 [17]. This
highlights the need for further work to characterize how
PD-1/L expression changes over the course of sepsis,
how this relates to outcome, and the optimal recruit-
ment window for any future trial of anti-PD-1 therapy.
With regard to nosocomial infection, we found that
lymphocyte PD-L1 expression was significantly higher in
those who subsequently developed an infection, but only
when the ICU length of stay exceeded 7 days. This may
be explained by the competing risk of nosocomial infec-
tion with early ICU discharge or death. The additional risk
provided by over-expression of these checkpoint inhibitors
may be overwhelmed by stronger risk factors for mortality
such as age, comorbidity and illness severity [14].
When interpreting our results, key limitations to con-
sider include the small sample size, the use of healthy
controls instead of non-sepsis critical illness controls,
and that this was a post-hoc sub-study designed to test a
hypothesis to inform future trials. We chose healthy
controls as critically ill patients exhibit a range of im-
mune deficits similar to those seen in patients with sep-
sis [24]; the use of non-infected critically ill controls
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could confound the association between PD-1 expression
and outcomes. The key strengths of the study include the
hypothesis-driven set of experiments that highlight the
need for further research to define PD-1, PD-L1 and PD-
L2 expression in sepsis, and its relationship to two com-
peting events - nosocomial infection and death [11].
Conclusions
In conclusion, our pilot study contributes to the further un-
derstanding of sepsis immunology by highlighting increased
expression of these checkpoint regulators in B cells, and
their differential expression by memory subset status in
both B and T cells. The utility of CD27 status in lympho-
cytes as a putative biomarker for patient enrichment in anti
PD-1 or anti PD-L1 trials warrants further study.
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sepsis and healthy controls. (DOCX 468 kb)
Additional file 8: Table S5. MFI of PD-1, PD-L1 and PD-L2 on CD27+ B
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Additional file 11: Figure S6. Comparison by nosocomial infection
status. Comparison of expression of PD-1, PD-L1 and PD-L2 between
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PD-L1 and PD-L2 expression by B and CD4+ T cells between patients
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patients with an ICU length of stay <7 days were excluded. (DOCX 237 kb)
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